Royalty Pharma (RPRX) Proceeds from sales of available for sale debt securities — Quarterly & Annual

Screener

Proceeds from sales of available for sale debt securities at other companies

Peoples Bancorp of North CarolinaPEBK

$0-100%

Solitario ResourcesXPL

$59K—

Chemung FinancialCHMG

$244.8M—

Chemung FinancialCHMG

$244.8M—

Peoples Financial ServicesPFIS

$32.4M+69.6%

Peoples Financial ServicesPFIS

$32.4M+69.6%

Other financials

Income statement

Revenue$674.1M+16.5%

Operating income$133.1M-36.5%

Net income$17.9M-44.4%

EPS (diluted)$0.04-42.9%

Balance sheet

Cash & equivalents$812.0M+28.5%

Total debt$9.0B+11.7%

Total equity$9.8B+3.1%

Total assets$19.8B+8.2%

Cash flow

Operating cash flow$728.5M+100%

Valuation

Market cap$25.28B+65.0%

Enterprise value$33.43B+47.4%

P/E31×+16.1×

P/S10×+3.3×

Profitability

Operating margin59.6%-20.2pp

Net margin32.1%-12.3pp

Returns & leverage

Return on equity8.5%-2.2pp

Debt / equity0.9×+0.1×

Current ratio2.8×+1.5×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept rprx:ProceedsFromAdditionalSalesOfAvailableForSaleDebtSecurities.

The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026. Open the filing →

Filed: Aug 5, 2026, 9:02 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001802768-26-000015

FAQ

What is Royalty Pharma's proceeds from sales of available for sale debt securities?: Royalty Pharma (RPRX) reported proceeds from sales of available for sale debt securities of $0 in Q2 2026.
What does proceeds from sales of available for sale debt securities mean?: Proceeds from sales of available for sale debt securities as reported by Royalty Pharma plc Class A Ordinary Shares.

Ask your AI about Royalty Pharma's proceeds from sales of available for sale debt securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk